OTC Monograph Offers Redemption For Some Unapproved Cough/Cold Drugs
This article was originally published in The Pink Sheet Daily
FDA could seize offending products or file injunctions against firms if the drugs were not listed with the agency before March 2 and firms do not discontinue production and shipping immediately.
You may also be interested in...
The agency doesn't know the drugs' share of the market, but uncertainties about their safety and efficacy constitute an untenable risk for consumers, CDER compliance chief says.
Over-the-counter pediatric cough/cold products relabeled "do not use" for children under 4 will reach shelves in the next few weeks in a voluntary program manufacturers coordinated with FDA
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.